BioGend Therapeutics Co., Ltd.

TWO:6733 Taiwan Biotechnology

Market Cap

$10.55K

NT$349.06K TWD

Market Cap Rank

#45038 Global

#1995 in Taiwan

Share Price

NT$35.00

Change (1 day)

-2.64%

52-Week Range

NT$27.85 - NT$49.00

All Time High

NT$49.00

BioGend Therapeutics Co., Ltd. - Asset Resilience Ratio

Latest as of December 2025: 36.79%

BioGend Therapeutics Co., Ltd. (6733) has an Asset Resilience Ratio of 36.79% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$300.00 Million

Cash + Short-term Investments

Total Assets

NT$815.38 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how BioGend Therapeutics Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down BioGend Therapeutics Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$300.00 Million	36.79%
Total Liquid Assets	NT$300.00 Million	36.79%

Asset Resilience Insights

Very High Liquidity: BioGend Therapeutics Co., Ltd. maintains exceptional liquid asset reserves at 36.79% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.